Stefania Basili

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/5739625/stefania-basili-publications-by-year.pdf

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

194 6,616 46 73 g-index

209 7,513 6.1 5.4 L-index

#	Paper	IF	Citations
194	Platelet and immune signature associated with a rapid response to the BNT162b2 mRNA Covid-19 Vaccine <i>Journal of Thrombosis and Haemostasis</i> , 2022 ,	15.4	4
193	Sex and Gender-Related Issues in Heart Failure Cardiology Clinics, 2022, 40, 259-268	2.5	
192	Flares of mixed cryoglobulinaemia vasculitis after vaccination against SARS-CoV-2. <i>Annals of the Rheumatic Diseases</i> , 2021 ,	2.4	3
191	Cutaneous adverse reactions after COVID-19 vaccines in a cohort of 2740 Italian subjects: An observational study. <i>Dermatologic Therapy</i> , 2021 , 34, e15153	2.2	10
190	Clinical course, management, and platelet activity assessment of splanchnic VITT: A case report. <i>Thrombosis Research</i> , 2021 , 208, 14-17	8.2	2
189	Rethinking of osteoporosis through a sex- and gender-informed approach in the COVID-19 era. <i>Minerva Obstetrics and Gynecology</i> , 2021 ,		1
188	Clinico-immunological outcomes of HCV-cured cryoglobulinemia: Lower relapse rate with interferon-based than interferon-free therapy. <i>Liver International</i> , 2021 , 41, 70-75	7.9	4
187	Prevalence, management and impact of chronic obstructive pulmonary disease in atrial fibrillation: a systematic review and meta-analysis of 4,200,000 patients. <i>European Heart Journal</i> , 2021 , 42, 3541-35	5 ² 4 ⁵	7
186	Prevalence of right ventricular dysfunction and impact on all-cause death in hospitalized patients with COVID-19: a systematic review and meta-analysis. <i>Scientific Reports</i> , 2021 , 11, 17774	4.9	9
185	Risk of cardiovascular events in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis <i>European Journal of Preventive Cardiology</i> , 2021 ,	3.9	4
184	Need for innovative and timely synthesis of evidence during Covid-19 outbreak. <i>European Journal of Internal Medicine</i> , 2020 , 77, 165-166	3.9	4
183	Antithrombotic treatment strategies after PCI. Lancet, The, 2020, 395, 866	40	
182	Gender-Related Determinants of Adherence to the Mediterranean Diet in Adults with Ischemic Heart Disease. <i>Nutrients</i> , 2020 , 12,	6.7	6
181	Sex and Gender-Related Issues in Heart Failure. <i>Heart Failure Clinics</i> , 2020 , 16, 121-130	3.3	8
180	Inherited and acquired thrombophilia in adults with retinal vascular occlusion: A systematic review and meta-analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2020 , 18, 3249-3266	15.4	8
179	Sex and Gender Differences in Ischemic Heart Disease: Endocrine Vascular Disease Approach (EVA) Study Design. <i>Journal of Cardiovascular Translational Research</i> , 2020 , 13, 14-25	3.3	7
178	Incidence and Recurrence of Portal Vein Thrombosis in Cirrhotic Patients. <i>Thrombosis and Haemostasis</i> , 2019 , 119, 496-499	7	18

(2018-2019)

177	Serum Albumin Is Inversely Associated With Portal Vein Thrombosis in Cirrhosis. <i>Hepatology Communications</i> , 2019 , 3, 504-512	6	31
176	The Sex-Specific Detrimental Effect of Diabetes and Gender-Related Factors on Pre-admission Medication Adherence Among Patients Hospitalized for Ischemic Heart Disease: Insights From EVA Study. <i>Frontiers in Endocrinology</i> , 2019 , 10, 107	5.7	4
175	Antiplatelet Drugs in the Management of Thrombotic/Ischemic Events in Peripheral Artery Disease 2019 , 1059-1066		1
174	Sex-Specific Cut-Offs for High-Sensitivity Cardiac Troponin: Is Less More?. <i>Cardiovascular Therapeutics</i> , 2019 , 2019, 9546931	3.3	22
173	Cardiomyopathy Associated with Diabetes: The Central Role of the Cardiomyocyte. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	40
172	Glutathione infusion before primary percutaneous coronary intervention: a randomised controlled pilot study. <i>BMJ Open</i> , 2019 , 9, e025884	3	3
171	Long-Term Relationship Between Atrial Fibrillation, Multimorbidity and Oral Anticoagulant Drug Use. <i>Mayo Clinic Proceedings</i> , 2019 , 94, 2427-2436	6.4	36
170	The phosphodiesterase 5 inhibitor sildenafil decreases the proinflammatory chemokine IL-8 in diabetic cardiomyopathy: in vivo and in vitro evidence. <i>Journal of Endocrinological Investigation</i> , 2019 , 42, 715-725	5.2	19
169	Low Rate of Intrahospital Deep Venous Thrombosis in Acutely Ill Medical Patients: Results From the AURELIO Study. <i>Mayo Clinic Proceedings</i> , 2019 , 94, 37-43	6.4	8
168	Influence of the oral status on cardiovascular diseases in an older Italian population. <i>International Journal of Immunopathology and Pharmacology</i> , 2018 , 32, 394632017751786	3	10
167	Platelet Count Does Not Predict Bleeding in Cirrhotic Patients: Results from the PRO-LIVER Study. <i>American Journal of Gastroenterology</i> , 2018 , 113, 368-375	0.7	48
166	Blood hydrogen peroxide break-down activity in healthy subjects and in patients at risk of cardiovascular events. <i>Atherosclerosis</i> , 2018 , 274, 29-34	3.1	9
165	Major adverse cardiovascular events in non-valvular atrial fibrillation with chronic obstructive pulmonary disease: the ARAPACIS study. <i>Internal and Emergency Medicine</i> , 2018 , 13, 651-660	3.7	9
164	Choice and Outcomes of Rate Control versus Rhythm Control in Elderly Patients with Atrial Fibrillation: A Report from the REPOSI Study. <i>Drugs and Aging</i> , 2018 , 35, 365-373	4.7	13
163	Sex differences in stroke and major adverse clinical events in patients with atrial fibrillation: A systematic review and meta-analysis of 993,600 patients. <i>International Journal of Cardiology</i> , 2018 , 269, 182-191	3.2	31
162	On-Treatment Platelet Reactivity is a Predictor of Adverse Events in Peripheral Artery Disease Patients Undergoing Percutaneous Angioplasty. <i>European Journal of Vascular and Endovascular Surgery</i> , 2018 , 56, 545-552	2.3	4
161	La sindrome metabolica: un modello clinico-terapeutico di endocrinologia di genere. <i>L Endocrinologo</i> , 2018 , 19, 123-127	О	
160	Anticoagulant therapy in patients with liver cirrhosis and portal vein thrombosis: insights for the clinician. <i>Therapeutic Advances in Gastroenterology</i> , 2018 , 11, 1756284818793561	4.7	21

159	Association of circulating CXCL10 and CXCL11 with systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 1845-1846	2.4	16
158	A Closer Look at Platelet Count and Prediction of Bleeding in Cirrhotic Patients. <i>American Journal of Gastroenterology</i> , 2018 , 113, 1397-1398	0.7	
157	Carotid plaque detection improves the predictive value of CHADS-VASc score in patients with non-valvular atrial fibrillation: The ARAPACIS Study. <i>International Journal of Cardiology</i> , 2017 , 231, 143-	149	16
156	Balancing thromboembolic and bleeding risk with non-vitamin K antagonist oral anticoagulants (NOACs): A systematic review and meta-analysis on gender differences. <i>Pharmacological Research</i> , 2017 , 117, 274-282	10.2	13
155	Moving Beyond Traditional Cardiovascular Risk Factors Toward Gendered Horizon. <i>Journal of Womeni</i> Health, 2017 , 26, 600-601	3	
154	Severe reduction of blood lysosomal acid lipase activity in cryptogenic cirrhosis: A nationwide multicentre cohort study. <i>Atherosclerosis</i> , 2017 , 262, 179-184	3.1	14
153	Comparison between "early" or "late" intravitreal injection of dexamethasone implant in branch (BRVO) or central (CRVO) retinal vein occlusion: six-months follow-up. <i>Cutaneous and Ocular Toxicology</i> , 2017 , 36, 224-230	1.8	3
152	Gut-derived endotoxin stimulates factor VIII secretion from endothelial cells. Implications for hypercoagulability in cirrhosis. <i>Journal of Hepatology</i> , 2017 , 67, 950-956	13.4	49
151	Sex and Circadian Periodicity of Cardiovascular Diseases: Are Women Sufficiently Represented in Chronobiological Studies?. <i>Heart Failure Clinics</i> , 2017 , 13, 719-738	3.3	11
150	Human cells involved in atherosclerosis have a sex. <i>International Journal of Cardiology</i> , 2017 , 228, 983-1	091	18
150 149	Human cells involved in atherosclerosis have a sex. <i>International Journal of Cardiology</i> , 2017 , 228, 983-1 Low-grade endotoxemia and platelet activation in cirrhosis. <i>Hepatology</i> , 2017 , 65, 571-581	11.2	18 71
149	Low-grade endotoxemia and platelet activation in cirrhosis. <i>Hepatology</i> , 2017 , 65, 571-581 Adherence to oral anticoagulant therapy in patients with atrial fibrillation. Focus on non-vitamin K	11.2	71
149	Low-grade endotoxemia and platelet activation in cirrhosis. <i>Hepatology</i> , 2017 , 65, 571-581 Adherence to oral anticoagulant therapy in patients with atrial fibrillation. Focus on non-vitamin K antagonist oral anticoagulants. <i>Thrombosis and Haemostasis</i> , 2017 , 117, 209-218 Treatment and Response to Statins: Gender-related Differences. <i>Current Medicinal Chemistry</i> , 2017 ,	11.2	71
149 148 147	Low-grade endotoxemia and platelet activation in cirrhosis. <i>Hepatology</i> , 2017 , 65, 571-581 Adherence to oral anticoagulant therapy in patients with atrial fibrillation. Focus on non-vitamin K antagonist oral anticoagulants. <i>Thrombosis and Haemostasis</i> , 2017 , 117, 209-218 Treatment and Response to Statins: Gender-related Differences. <i>Current Medicinal Chemistry</i> , 2017 , 24, 2628-2638 Sex Differences in Type-2 Diabetes: Implications for Cardiovascular Risk Management. <i>Current</i>	7 4-3	71 124 15
149 148 147	Low-grade endotoxemia and platelet activation in cirrhosis. <i>Hepatology</i> , 2017 , 65, 571-581 Adherence to oral anticoagulant therapy in patients with atrial fibrillation. Focus on non-vitamin K antagonist oral anticoagulants. <i>Thrombosis and Haemostasis</i> , 2017 , 117, 209-218 Treatment and Response to Statins: Gender-related Differences. <i>Current Medicinal Chemistry</i> , 2017 , 24, 2628-2638 Sex Differences in Type-2 Diabetes: Implications for Cardiovascular Risk Management. <i>Current Pharmaceutical Design</i> , 2017 , 23, 1471-1476	7 4-3	71 124 15
149 148 147 146	Low-grade endotoxemia and platelet activation in cirrhosis. <i>Hepatology</i> , 2017 , 65, 571-581 Adherence to oral anticoagulant therapy in patients with atrial fibrillation. Focus on non-vitamin K antagonist oral anticoagulants. <i>Thrombosis and Haemostasis</i> , 2017 , 117, 209-218 Treatment and Response to Statins: Gender-related Differences. <i>Current Medicinal Chemistry</i> , 2017 , 24, 2628-2638 Sex Differences in Type-2 Diabetes: Implications for Cardiovascular Risk Management. <i>Current Pharmaceutical Design</i> , 2017 , 23, 1471-1476 Antiplatelet Therapy in Peripheral Artery Disease 2017 , 1381-1390 Aspirin and renal insufficiency progression in patients with atrial fibrillation and chronic kidney	7 4-3 3-3	71 124 15 8

(2014-2016)

141	Ageing/Menopausal Status in Healthy Women and Ageing in Healthy Men Differently Affect Cardiometabolic Parameters. <i>International Journal of Medical Sciences</i> , 2016 , 13, 124-32	3.7	23
140	Ankle-Brachial Index and cardiovascular events in atrial fibrillation. The ARAPACIS Study. <i>Thrombosis and Haemostasis</i> , 2016 , 115, 856-63	7	26
139	Portal vein thrombosis relevance on liver cirrhosis: Italian Venous Thrombotic Events Registry. <i>Internal and Emergency Medicine</i> , 2016 , 11, 1059-1066	3.7	62
138	Chronotype, gender and general health. <i>Chronobiology International</i> , 2016 , 33, 863-82	3.6	123
137	Relationship between carotid intima-media thickness and non valvular atrial fibrillation type. <i>Atherosclerosis</i> , 2015 , 238, 350-5	3.1	23
136	Frequency of Left Ventricular Hypertrophy in Non-Valvular Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2015 , 116, 877-82	3	21
135	Platelet Function: the Janus face of haemostasis in cirrhosis. <i>Thrombosis Research</i> , 2015 , 135, 1224-5	8.2	2
134	Adherence to antibiotic treatment guidelines and outcomes in the hospitalized elderly with different types of pneumonia. <i>European Journal of Internal Medicine</i> , 2015 , 26, 330-7	3.9	18
133	Impact of sex and gender on the efficacy of antiplatelet therapy: the female perspective. <i>Journal of Atherosclerosis and Thrombosis</i> , 2015 , 22, 109-25	4	13
132	Atrial fibrillation is not associated with increased risk of venous thromboembolism: Results from ARAPACIS study. <i>Thrombosis and Haemostasis</i> , 2015 , 114, 655	7	1
131	Relationship between low Ankle-Brachial Index and rapid renal function decline in patients with atrial fibrillation: a prospective multicentre cohort study. <i>BMJ Open</i> , 2015 , 5, e008026	3	17
130	VBIVI T lymphocytes activation as a novel approach to test efficacy of different bisphosphonates. <i>Endocrine</i> , 2015 , 48, 346-8	4	1
129	Old And New Oral Anticoagulants In Management Of Atrial Fibrillation: A Double-Edged Sword For Women. <i>Current Vascular Pharmacology</i> , 2015 , 13, 738-48	3.3	8
128	Gout, allopurinol intake and clinical outcomes in the hospitalized multimorbid elderly. <i>European Journal of Internal Medicine</i> , 2014 , 25, 847-52	3.9	1
127	Gender-differences in disease distribution and outcome in hospitalized elderly: data from the REPOSI study. <i>European Journal of Internal Medicine</i> , 2014 , 25, 617-23	3.9	62
126	Multimorbidity and polypharmacy in the elderly: lessons from REPOSI. <i>Internal and Emergency Medicine</i> , 2014 , 9, 723-34	3.7	95
125	Medication prescription and adherence disparities in non valvular atrial fibrillation patients: an Italian portrait from the ARAPACIS study. <i>Internal and Emergency Medicine</i> , 2014 , 9, 861-70	3.7	21
124	Asymptomatic peripheral artery disease and antiplatelet management. <i>Vasa - European Journal of Vascular Medicine</i> , 2014 , 43, 309-25	1.9	8

123	Aspirin reload before elective percutaneous coronary intervention: impact on serum thromboxane b2 and myocardial reperfusion indexes. <i>Circulation: Cardiovascular Interventions</i> , 2014 , 7, 577-84	6	12
122	Role of platelets in NOX2 activation mediated by TNFIIn heart failure. <i>Internal and Emergency Medicine</i> , 2014 , 9, 179-85	3.7	15
121	Polyunsaturated fatty acids balance affects platelet NOX2 activity in patients with liver cirrhosis. Digestive and Liver Disease, 2014 , 46, 632-8	3.3	9
120	Reply: ankle-brachial index in patients with nonvalvular atrial fibrillation. <i>Journal of the American College of Cardiology</i> , 2014 , 63, 1457-8	15.1	1
119	Prevalence of peripheral artery disease by abnormal ankle-brachial index in atrial fibrillation: implications for risk and therapy. <i>Journal of the American College of Cardiology</i> , 2013 , 62, 2255-6	15.1	44
118	Prophylaxis of venous thromboembolism in elderly patients with multimorbidity. <i>Internal and Emergency Medicine</i> , 2013 , 8, 509-20	3.7	17
117	The predictive ability of bleeding risk stratification models in very old patients on vitamin K antagonist treatment for venous thromboembolism: results of the prospective collaborative EPICA study. <i>Journal of Thrombosis and Haemostasis</i> , 2013 , 11, 1053-8	15.4	32
116	NOX2 up-regulation is associated with artery dysfunction in patients with peripheral artery disease. <i>International Journal of Cardiology</i> , 2013 , 165, 184-92	3.2	45
115	Joint use of cardio-embolic and bleeding risk scores in elderly patients with atrial fibrillation. <i>European Journal of Internal Medicine</i> , 2013 , 24, 800-6	3.9	11
114	Cholesterol-adjusted vitamin E serum levels are associated with cardiovascular events in patients with non-valvular atrial fibrillation. <i>International Journal of Cardiology</i> , 2013 , 168, 3241-7	3.2	9
113	Risk factors for hospital readmission of elderly patients. <i>European Journal of Internal Medicine</i> , 2013 , 24, 45-51	3.9	58
112	Prognostic role of plasma von Willebrand factor and soluble E-selectin levels for future cardiovascular events in a 'real-world' community cohort of patients with atrial fibrillation. <i>European Journal of Clinical Investigation</i> , 2013 , 43, 1032-8	4.6	28
111	Antiplatelet therapy in peripheral artery disease. Handbook of Experimental Pharmacology, 2012, 547-6	33.2	11
110	"Pitfalls in assessing platelet activation status in patients with liver disease: authors' reply". <i>Liver International</i> , 2012 ,	7.9	
109	Pitfalls in assessing platelet activation status in patients with liver disease: authors Peply. <i>Liver International</i> , 2012 , 32, 1028-1028	7.9	
108	Oxidative stress and platelet activation in subjects with moderate hyperhomocysteinaemia due to MTHFR 677 C-To polymorphism. <i>Thrombosis and Haemostasis</i> , 2012 , 108, 533-42	7	17
107	Reply to: Platelet function in patients with cirrhosis. <i>Journal of Hepatology</i> , 2012 , 56, 994-995	13.4	1
106	Immediate antioxidant and antiplatelet effect of atorvastatin via inhibition of Nox2. <i>Circulation</i> , 2012 , 126, 92-103	16.7	115

(2010-2012)

105	Peripheral artery disease and atrial fibrillation: a potentially dangerous combination. <i>Internal and Emergency Medicine</i> , 2012 , 7, 213-8	3.7	27
104	Platelet isoprostane overproduction in diabetic patients treated with aspirin. <i>Diabetes</i> , 2012 , 61, 1626-3	32 .9	41
103	Factor seven activating protease activity levels in women with recurrent pregnancy loss. <i>Reproductive Sciences</i> , 2012 , 19, 317-21	3	2
102	Patients with liver cirrhosis suffer from primary haemostatic defects? Fact or fiction?. <i>Journal of Hepatology</i> , 2011 , 55, 1415-27	13.4	131
101	Ascorbic acid infusion blunts CD40L upregulation in patients undergoing coronary stent. <i>Cardiovascular Therapeutics</i> , 2011 , 29, 385-94	3.3	17
100	NADPH oxidase-mediated platelet isoprostane over-production in cirrhotic patients: implication for platelet activation. <i>Liver International</i> , 2011 , 31, 1533-40	7.9	33
99	Importance of haplotype analysis in association studies considering VEGF promoter polymorphisms. <i>Clinical Biochemistry</i> , 2011 , 44, 748	3.5	
98	Anoxia-reoxygenation enhances platelet thromboxane A2 production via reactive oxygen species-generated NOX2: effect in patients undergoing elective percutaneous coronary intervention. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2011 , 31, 1766-71	9.4	31
97	Nutrition, supplements, and vitamins in platelet function and bleeding. <i>Circulation</i> , 2010 , 121, 1033-44	16.7	59
96	TNFA gene promoter polymorphisms and susceptibility to recurrent pregnancy loss in Italian women. <i>Reproductive Sciences</i> , 2010 , 17, 659-66	3	18
95	Letter by Violi et al regarding article, "Association of cyclooxygenase-1-dependent and -independent platelet function assays with adverse clinical outcomes in aspirin-treated patients presenting for cardiac catheterization". <i>Circulation</i> , 2010 , 122, e429; author reply e430	16.7	
94	Atorvastatin inhibits gp91phox circulating levels in patients with hypercholesterolemia. Arteriosclerosis, Thrombosis, and Vascular Biology, 2010 , 30, 360-7	9.4	91
93	The coagulopathy of chronic liver disease: is there a causal relationship with bleeding? Yes. <i>European Journal of Internal Medicine</i> , 2010 , 21, 62-4	3.9	26
92	Predictive value of thrombopath determination in women with infertility and pregnancy complications. <i>Clinica Chimica Acta</i> , 2010 , 411, 37-42	6.2	5
91	Comparison of efficacy of antiplatelet treatments for patients with claudication. A meta-analysis. <i>Thrombosis and Haemostasis</i> , 2010 , 103, 766-73	7	25
90	Nutraceuticals in the early infancy. <i>Cardiovascular Therapeutics</i> , 2010 , 28, 236-45	3.3	2
89	Atorvastatin inhibits oxidative stress via adiponectin-mediated NADPH oxidase down-regulation in hypercholesterolemic patients. <i>Atherosclerosis</i> , 2010 , 213, 225-34	3.1	44
88	Intravenous ascorbic acid infusion improves myocardial perfusion grade during elective percutaneous coronary intervention: relationship with oxidative stress markers. <i>JACC:</i> Cardiovascular Interventions, 2010 , 3, 221-9	5	51

87	VEGF-A gene promoter polymorphisms and microvascular complications in patients with essential hypertension. <i>Clinical Biochemistry</i> , 2010 , 43, 1090-5	3.5	16
86	Thromboxane and prostacyclin biosynthesis in heart failure of ischemic origin: effects of disease severity and aspirin treatment. <i>Journal of Thrombosis and Haemostasis</i> , 2010 , 8, 914-22	15.4	15
85	CD40 ligand and MCP-1 as predictors of cardiovascular events in diabetic patients with stroke. <i>Journal of Atherosclerosis and Thrombosis</i> , 2009 , 16, 707-13	4	49
84	Role of NADPH oxidase in atherosclerosis. <i>Future Cardiology</i> , 2009 , 5, 83-92	1.3	56
83	Hereditary deficiency of gp91(phox) is associated with enhanced arterial dilatation: results of a multicenter study. <i>Circulation</i> , 2009 , 120, 1616-22	16.7	113
82	Myeloperoxidase overexpression in children with hypercholesterolemia. <i>Atherosclerosis</i> , 2009 , 205, 239	- 4 3	15
81	In vivo platelet activation is responsible for enhanced vascular endothelial growth factor levels in hypertensive patients. <i>Clinica Chimica Acta</i> , 2008 , 388, 33-7	6.2	21
80	Association of low-grade inflammation and platelet activation in patients with hypertension with microalbuminuria. <i>Clinical Science</i> , 2008 , 114, 449-55	6.5	22
79	Aspirin in asymptomatic patients with a confirmed positivity of antiphospholipid antibodies. <i>Internal and Emergency Medicine</i> , 2008 , 3, 373-4	3.7	1
78	Etanercept in the treatment of rheumatoid arthritis: clinical follow-up over one year by ultrasonography. <i>Clinical Rheumatology</i> , 2008 , 27, 491-6	3.9	51
77	Autonomic dysfunction and microvascular damage in systemic sclerosis. <i>Clinical Rheumatology</i> , 2007 , 26, 1278-83	3.9	35
76	CD40/CD40L system and vascular disease. <i>Internal and Emergency Medicine</i> , 2007 , 2, 256-68	3.7	76
75	Contribution of platelet-derived CD40 ligand to inflammation, thrombosis and neoangiogenesis. <i>Current Medicinal Chemistry</i> , 2007 , 14, 2170-80	4.3	58
74	Prognostic significance of interleukin-6 measurement in the diagnosis of acute myocardial infarction in emergency department. <i>Clinica Chimica Acta</i> , 2007 , 381, 151-6	6.2	8
73	Low-density lipoprotein-lowering medication and platelet function. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , 2006 , 35, 346-54		19
72	Thromboxane-dependent CD40 ligand release in type 2 diabetes mellitus. <i>Journal of the American College of Cardiology</i> , 2006 , 47, 391-7	15.1	91
71	Insulin resistance as a determinant of platelet activation in obese women. <i>Journal of the American College of Cardiology</i> , 2006 , 48, 2531-8	15.1	98
70	Endothelial dysfunction and oxidative stress in arterial hypertension. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2006 , 16, 222-33	4.5	83

69	Soluble CD40L and cardiovascular risk in asymptomatic low-grade carotid stenosis. Stroke, 2005, 36, 673	3 6 57	54
68	Circulating transforming growth factor-beta1 levels in asymptomatic carotid plaques. <i>Stroke</i> , 2005 , 36, 525-6; author reply 525-6	6.7	2
67	Helicobacter pylori infection causes persistent platelet activation in vivo through enhanced lipid peroxidation. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2005 , 25, 246-51	9.4	25
66	Oxidant stress and platelet activation in hypercholesterolemia. <i>Antioxidants and Redox Signaling</i> , 2004 , 6, 747-56	8.4	43
65	Soluble CD40 ligand plasma levels in lung cancer. Clinical Cancer Research, 2004, 10, 610-4	12.9	52
64	Platelet activation in type 2 diabetes mellitus. <i>Journal of Thrombosis and Haemostasis</i> , 2004 , 2, 1282-91	15.4	322
63	Inflammation, insulin resistance, and obesity. Current Atherosclerosis Reports, 2004, 6, 424-31	6	116
62	Prognostic value of soluble P-selectin levels in colorectal cancer. <i>International Journal of Cancer</i> , 2004 , 111, 404-8	7.5	31
61	Correlation between tumor necrosis factor-alpha and D-dimer levels in non-small cell lung cancer patients. <i>Lung Cancer</i> , 2004 , 44, 303-10	5.9	22
60	Absolute neutrophil counts and fibrinogen levels as an aid in the early diagnosis of acute myocardial infarction. <i>Acta Cardiologica</i> , 2004 , 59, 135-40	0.9	4
59	Association of inflammation markers with impaired insulin sensitivity and coagulative activation in obese healthy women. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003 , 88, 5321-6	5.6	99
58	Platelet activation, inflammatory mediators and hypercholesterolemia. <i>Current Vascular Pharmacology</i> , 2003 , 1, 157-69	3.3	57
57	Association between serum carcinoembryonic antigen and endothelial cell adhesion molecules in colorectal cancer. <i>Oncology</i> , 2003 , 65, 132-8	3.6	15
56	Vascular endothelial growth factor (VEGF-A) plasma levels in non-small cell lung cancer: relationship with coagulation and platelet activation markers. <i>Thrombosis and Haemostasis</i> , 2003 , 89, 177-184	7	40
55	Increased circulating Interleukin-18 levels in centenarians with no signs of vascular disease: another paradox of longevity?. <i>Experimental Gerontology</i> , 2003 , 38, 669-72	4.5	50
54	Leptin increase is associated with markers of the hemostatic system in obese healthy women. Journal of Thrombosis and Haemostasis, 2003, 1, 2330-4	15.4	33
53	In vivo platelet activation is associated with increased plasma levels of vascular endothelial growth factor. <i>Journal of Thrombosis and Haemostasis</i> , 2003 , 1, 853-4	15.4	6
52	Enhanced lipid peroxidation and platelet activation in the early phase of type 1 diabetes mellitus: role of interleukin-6 and disease duration. <i>Circulation</i> , 2003 , 107, 3199-203	16.7	119

51	Enhanced interleukin-1beta in hypercholesterolemia: effects of simvastatin and low-dose aspirin. <i>Circulation</i> , 2003 , 108, 1673-5	16.7	32
50	Serum Metalloproteinase 9 Levels in Patients with Coronary Artery Disease: A Novel Marker of Inflammation. <i>Journal of Investigative Medicine</i> , 2003 , 51, 295	2.9	32
49	Prognostic value of serum and tumor tissue CA 72-4 content in gastric cancer. <i>International Journal of Biological Markers</i> , 2003 , 18, 21-7	2.8	18
48	Platelet activation in obese women: role of inflammation and oxidant stress. <i>JAMA - Journal of the American Medical Association</i> , 2002 , 288, 2008-14	27.4	406
47	Tumor necrosis factor-alpha and myocardial function in patients with myotonic dystrophy type 1. <i>Journal of the Neurological Sciences</i> , 2002 , 201, 59-64	3.2	10
46	Soluble selectin levels in patients with lung cancer. <i>International Journal of Biological Markers</i> , 2002 , 17, 56-62	2.8	15
45	Increased soluble P-selectin levels in hepatitis C virus-related chronic hepatitis: correlation with viral load. <i>Journal of Investigative Medicine</i> , 2001 , 49, 407-12	2.9	17
44	Determinants of enhanced thromboxane biosynthesis in renal transplantation. <i>Kidney International</i> , 2001 , 59, 1574-9	9.9	18
43	Reply to: Lipoprotein (a) and chronic obstructive pulmonary disease. <i>Atherosclerosis</i> , 2001 , 155, 525-6	3.1	O
42	Effects of mud-pack treatment on plasma cytokine and soluble adhesion molecule levels in healthy volunteers. <i>Clinica Chimica Acta</i> , 2001 , 314, 209-14	6.2	16
41	Rebuttal to Circulating IL-6 Levels in Chronic Obstructive Pulmonary Disease. <i>Thrombosis and Haemostasis</i> , 2001 , 85, 373-373	7	1
40	Morphologic left ventricular patterns and prevalence of high-grade ventricular arrhythmias in the normotensive and hypertensive elderly. <i>Advances in Therapy</i> , 2000 , 17, 222-9	4.1	7
39	Natural history of cardiac involvement in myotonic dystrophy (Steinert's disease): a 13-year follow-up study. <i>Advances in Therapy</i> , 2000 , 17, 238-51	4.1	18
38	Inhibition of tissue-factor-mediated thrombin generation by simvastatin. <i>Atherosclerosis</i> , 2000 , 149, 111	5 1	86
37	Simvastatin inhibits the monocyte expression of proinflammatory cytokines in patients with hypercholesterolemia. <i>Journal of the American College of Cardiology</i> , 2000 , 36, 427-31	15.1	165
36	Soluble P-selectin and proinflammatory cytokines in patients with polygenic type IIa hypercholesterolemia. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , 1999 , 29, 277-85		6
35	Clotting Activation after Transjugular Intrahepatic Portosystemic Stent Shunt. <i>Thrombosis and Haemostasis</i> , 1999 , 81, 711-714	7	7
34	Vitamin E Reduces Monocyte Tissue Factor Expression in Cirrhotic Patients. <i>Blood</i> , 1999 , 93, 2945-2950	2.2	47

33	Determinants of enhanced thromboxane biosynthesis in patients with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 1999 , 42, 2689-97		29
32	Cardiac critical events in myotonic dystrophy: relationship with the severity of neuromuscular disease. <i>European Journal of Internal Medicine</i> , 1999 , 10, 198-201	3.9	
31	Endotoxaemia, hyperfibrinolysis, and bleeding in cirrhosis. <i>Lancet, The</i> , 1999 , 353, 1102	40	6
30	Lipoprotein(a) serum levels in patients affected by chronic obstructive pulmonary disease. <i>Atherosclerosis</i> , 1999 , 147, 249-52	3.1	36
29	Vitamin E Reduces Monocyte Tissue Factor Expression in Cirrhotic Patients. <i>Blood</i> , 1999 , 93, 2945-2950	2.2	11
28	Chronic obstructive pulmonary disease is associated with an increase in urinary levels of isoprostane F2alpha-III, an index of oxidant stress. <i>American Journal of Respiratory and Critical Care Medicine</i> , 1998 , 158, 1709-14	10.2	225
27	Enhanced expression of monocyte tissue factor in patients with liver cirrhosis. <i>Gut</i> , 1998 , 43, 428-32	19.2	46
26	Increased Thromboxane Metabolites Excretion in Liver Cirrhosis. <i>Thrombosis and Haemostasis</i> , 1998 , 79, 747-751	7	22
25	Proinflammatory cytokines and hemostatic system in patients with chronic obstructive pulmonary disease. <i>Platelets</i> , 1997 , 8, 255-9	3.6	9
24	Enhanced thromboxane biosynthesis in patients with chronic obstructive pulmonary disease. The Chronic Obstructive Bronchitis and Haemostasis Study Group. <i>American Journal of Respiratory and Critical Care Medicine</i> , 1997 , 156, 1794-9	10.2	61
23	Lipoprotein (a) serum levels in patients with hepatocarcinoma. Clinica Chimica Acta, 1997, 262, 53-60	6.2	11
22	Polyol pathway activation and glutathione redox status in non-insulin-dependent diabetic patients. <i>Metabolism: Clinical and Experimental</i> , 1997 , 46, 1194-8	12.7	66
21	Simvastatin reduces monocyte-tissue-factor expression type IIa hypercholesterolaemia. <i>Lancet, The</i> , 1997 , 350, 1222	40	50
20	Hepatitis C virus, antiphospholipid antibodies, and thrombosis. <i>Hepatology</i> , 1997 , 25, 782	11.2	9
19	Coexistence of anti-phospholipid antibodies and endothelial perturbation in systemic lupus erythematosus patients with ongoing prothrombotic state. <i>Circulation</i> , 1997 , 95, 1425-32	16.7	46
18	Diabetes mellitus, hypercholesterolemia, and hypertension but not vascular disease per se are associated with persistent platelet activation in vivo. Evidence derived from the study of peripheral arterial disease. <i>Circulation</i> , 1997 , 96, 69-75	16.7	142
17	Ongoing Prothrombotic State in the Portal Circulation of Cirrhotic Patients. <i>Thrombosis and Haemostasis</i> , 1997 , 77, 044-047	7	47
16	Signal-averaged electrocardiography and echocardiography in the evaluation of myocardial involvement in progressive systemic sclerosis. <i>International Journal of Cardiology</i> , 1996 , 53, 171-7	3.2	6

15	Bleeding time does not predict gastrointestinal bleeding in patients with cirrhosis. The CALC Group. Coagulation Abnormalities in Liver Cirrhosis. <i>Journal of Hepatology</i> , 1996 , 24, 574-80	13.4	32
14	Potential usefulness of antiplatelet agents in patients with chronic obstructive pulmonary disease. <i>Thrombosis Research</i> , 1996 , 84, 279-84	8.2	2
13	Association between High Values of D-dimer and Tissue-plasminogen Activator Activity and First Gastrointestinal Bleeding in Cirrhotic Patients. <i>Thrombosis and Haemostasis</i> , 1996 , 76, 177-183	7	39
12	Association between low-grade disseminated intravascular coagulation and endotoxemia in patients with liver cirrhosis. <i>Gastroenterology</i> , 1995 , 109, 531-9	13.3	104
11	Prognostic value of clotting and fibrinolytic systems in a follow-up of 165 liver cirrhotic patients*1. Hepatology, 1995 , 22, 96-100	11.2	2
10	Apolipoproteins C-II and C-III in peripheral arterial disease. <i>Angiology</i> , 1994 , 45, 131-6	2.1	3
9	Relationship between lipoprotein(a) levels in serum and some indices of protein synthesis in liver cirrhosis. <i>Clinica Chimica Acta</i> , 1994 , 224, 125-9	6.2	12
8	Bleeding time in patients with cirrhosis: relation with degree of liver failure and clotting abnormalities. C.A.L.C. Group. Coagulation Abnormalities in Cirrhosis Study Group. <i>Journal of Hepatology</i> , 1994 , 20, 531-6	13.4	68
7	Prevalence of lupus anticoagulant in patients with cirrhosis: relationship with beta-2-glycoprotein I plasma levels. <i>Journal of Hepatology</i> , 1994 , 21, 1086-91	13.4	27
6	Relation between lupus anticoagulant and splanchnic venous thrombosis in cirrhosis of the liver. <i>BMJ: British Medical Journal</i> , 1994 , 309, 239-40		43
5	Hypercoagulability State in Patients with Chronic Obstructive Pulmonary Disease. <i>Thrombosis and Haemostasis</i> , 1994 , 72, 343-346	7	59
4	Hyperfibrinolysis Resulting from Clotting Activation in Patients with Different Degrees of Cirrhosis. Hepatology, 1993 , 17, 78-83	11.2	79
3	Hyperfibrinolysis Resulting from Clotting Activation in Patients with Different Degrees of Cirrhosis 1993 , 17, 78		1
2	Improvement of blood gas levels after calcium-heparin treatment in patients with chronic obstructive pulmonary disease. <i>Thrombosis Research</i> , 1992 , 68, 435-40	8.2	1
1	Hyperfibrinolysis increases the risk of gastrointestinal hemorrhage in patients with advanced cirrhosis. <i>Hepatology</i> , 1992 , 15, 672-6	11.2	79